Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Engineered nanoparticles (ENM) cause lung pathology by increasing lysosomal membrane permeability and activation of the NLRP3 inflammasome in macrophages.

Authors
Holian-A; Hamilton-R; Girtsman-T; Migliaccio-C; Buford-M; Shaw-P; Herritt-L; Mitra-S; Sager-T; Porter-D; Wu-N
Source
Eur J Clin Invest 2013 Apr; 43(Suppl 1):5
NIOSHTIC No.
20042596
Abstract
Background: The purpose of the study was to determine the mechanism of bioactivity of ENM by linking their ability to cause lysosomal dysfunction and activation of the NLRP3 inflammasome in macrophages to lung pathology. Materials and methods: A library (raw and modified MWCNT, metal oxides of different shapes and modifications, and silver of different sizes) of nanomaterials were prepared, characterized and tested in vitro using THP-1 macrophages, alveolar macrophages isolated from C57Bl/6 mice and in vivo using C57Bl/6 mice. Assessments were made of: uptake, lysosomal dysfunction, cathepsin B release, NLRP3 inflammasome activation, IL-1beta release, lung inflammation and pathology. Results: All ENM were effectively taken up by macrophages. However, only bioactive ENM caused phagolysosomal membrane disruption, cathepsin B release, NLRP3 inflammasome activation and IL-1beta release from both macrophage models. THP-1 cells proved to be a more sensitive model than primary macrophages. Furthermore, the relative activity of ENM in THP-1 cells was a good predictor of in vivo NLRP3 inflammasome activation, inflammation and lung pathology. Long aspect ENM of the same material were more active than spherical and dependent on length. Carboxylation of ENM decreased bioactivity and surface area was a good predictor of bioactivity of spherical materials. Conclusions: ENM cause lung inflammation and injury through activation of the NLRP3 inflammasome and there is now increasing knowledge linking ENM structure with bioactivity.
Keywords
Nanotechnology; Respiratory-system-disorders; Pulmonary-system-disorders; Lung-cells; Lung-disorders; Lung-function; Lung-irritants; Lung-tissue; Pathology; Immune-reaction; Bioactivation; Silver-compounds; Metal-oxides; In-vitro-study; Alveolar-cells; In-vivo-study; Laboratory-animals; Laboratory-testing; Cellular-uptake; Phagocytic-activity; Analytical-models; Cellular-reactions
CODEN
EJCIB8
CAS No.
7440-22-4
Publication Date
20130401
Document Type
Abstract
Fiscal Year
2013
NTIS Accession No.
NTIS Price
Identifying No.
B20130531
ISSN
0014-2972
NIOSH Division
HELD
Priority Area
Manufacturing
Source Name
European Journal of Clinical Investigation
State
NJ; MT; OH; WV
TOP